Zavante Therapeutics’ ZOLYD™ Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections

Zavante Therapeutics’ ZOLYD™ Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections

READ FULL TEXT

Leave a Reply

Your email address will not be published.